Urinary Tract Infection in ChildrenSymptoms, Doctors, Treatments, Advances & More
Learn About Urinary Tract Infection in Children
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
The Paul C. Gaffney Division Of Pediatric Hospital Medicine
Catherine Forster, MD, specializes in pediatric hospital medicine and is board-certified by the American Board of Pediatrics. She is affiliated with UPMC Children's Hospital of Pittsburgh. Dr. Forster received her medical degree from Thomas Jefferson University Sidney Kimmel Medical College and completed her residency at Boston Children's Hospital, followed by a fellowship at Cincinnati Children's Hospital Medical Center. Dr. Forster is rated as an Elite provider by MediFind in the treatment of Urinary Tract Infection in Children. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Urinary Tract Infection in Children and Micrognathia. Dr. Forster is board certified in American Board Of Pediatrics and American Board Of Pediatrics.
University Of Pittsburgh Physicians, Department Of Pediatrics
Nader Shaikh, MD, MPH, is a professor of pediatrics and clinical and translational Science at the University of Pittsburgh School of Medicine in the Division of General Academic Pediatrics. Dr. Shaikh is rated as an Elite provider by MediFind in the treatment of Urinary Tract Infection in Children. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Urinary Tract Infection in Children, Otitis Media with Effusion, Streptococcal Group A Infection, Neonatal Sepsis, and Myringotomy. Dr. Shaikh is board certified in American Board Of Pediatrics.
Pediatric Primary Care (Upper Level) In Oakland
Dr. Alejandro Hoberman graduated from medical school and general pediatrics residency in Buenos Aires, Argentina. He completed a General Academic Pediatrics fellowship at UPMC Children’s Hospital of Pittsburgh and joined the faculty at the University of Pittsburgh.He currently heads the Division of General Academic Pediatrics, is the executive vice chair and vice chair for Clinical Research in the Department of Pediatrics, and has been established as the Jack L. Paradise Distinguished Service Professor in honor of his research mentor. Dr. Hoberman also has administrative responsibilities as the president of UPMC Children’s Community Pediatrics, the largest primary care pediatrics organization in western and central Pa. with 58 offices including Express Care locations and over 1M yearly visits.Dr. Hoberman is very involved in research related to acute otitis media (AOM). He has contributed studies to enhance prevention, diagnosis, and treatment of this frequently occurring condition. He has also contributed studies related to prevalence, diagnosis, treatment, and follow-up imaging of urinary tract infections (UTI) in children.Click here to view Dr. Hoberman’s Department of Pediatrics bio page which has more information about his specific research endeavors, including publications, leadership positions, awards, and more.Click here to view Dr. Hoberman’s full list of publications from PubMed. Dr. Hoberman is rated as an Elite provider by MediFind in the treatment of Urinary Tract Infection in Children. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Urinary Tract Infection in Children, Otitis Media with Effusion, High Blood Pressure in Infants, Diarrhea, and Myringotomy. Dr. Hoberman is board certified in American Board Of Pediatrics.
Summary: Urinary tract infections are very common in pediatrics. Urinary antibiotic prophylaxis is commonly used in children with malformative uropathies. Long-term, low-dose antibiotic prophylaxis with trimethoprim-sulfamethoxazole has been associated with a decrease in the number of urinary tract infections in susceptible children, but not systematically with a decrease in the risk of renal scarring (dep...
Summary: The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).